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Introduction
There is some consensus that prediction of hepatic clearance from in vitro systems is in urgent need of refinement because of several-fold average underprediction combined with high imprecision (Hallifax et al., 2010; Bowman and Benet, 2016) . This bias is clearance-dependent, particularly for hepatocytes, regardless of human or rat origin, and is largely independent of drug type in terms of uptake mechanism (Wood et al., 2017) . A methodological deficiency at the level of incubation of drug with hepatocytes is thus implied and, with a lack of standardisation among reported prediction studies, a fundamental re-assessment of assay procedure is needed.
Potential causes of clearance-dependent underprediction from hepatocyte incubations appear to include co-factor exhaustion (Swales and Utesch, 1998; Hengstler et al., 2000; Wang et al., 2005) , rate-limiting membrane permeation (Hallifax et al., 2010; Foster et al., 2011) and rate-limiting diffusion through the unstirred water layer (UWL), although none of these putative factors has been conclusively investigated for this type of assay. Effective assessment could be complicated by other, simultaneous, sources of bias (but independent of clearance), adding to the imprecision. These could include excessive substrate concentration resulting in saturation of metabolic enzymes (Klopf and Worboys, 2010) , or failure to distinguish un-metabolised drug cleared by uptake transport (Shitara et al., 2006; Soars et al., 2007; Watanabe et al., 2010) . This report focusses on drugs predominantly undergoing passive hepatic uptake.
Cofactor depletion from hepatocytes has been evidenced by reduced metabolic activity in cryopreserved hepatocytes compared with fresh hepatocytes (Swales et al., 1996; Hewitt et al., 2000; Hewitt and Utesch, 2004) . However, a recent analysis of published predictions demonstrated no bias in intrinsic clearance between fresh and cryopreserved human hepatocytes, implying a lack of cryopreservation impact. It is not clear, though, whether rapidly metabolised drugs could be limited by co-factor replenishment rate in vitro in a way that does not reflect the in vivo situation (Wood et al., 2017) .
In the parallel field of in vitro assessment of drug gut permeability, the involvement of the UWL is well recognised (Naruhashi et al., 2003; Avdeef et al., 2004) . The UWL is a solute-dependent region adjacent to a cellular membrane in which solvent movement is markedly slower than in the bulk medium, causing a diffusional barrier to passage both into and out of a cell (Korjamo et al., 2009) . This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 12, 2017 as DOI: 10.1124 at ASPET Journals on January 6, 2018 dmd.aspetjournals.org The presence of an UWL has been demonstrated to substantially reduce the apparent permeability of highly permeable compounds (Naruhashi et al., 2003; Korjamo et al., 2009) ). At gut lumen/enterocyte or extracellular fluid/cell interfaces in vivo, an UWL can also exist, although generally at considerably lesser depths compared with some in vitro situations (Lennernas, 1998) . While the need to control the UWL phenomenon in vitro has been recognised for absorption prediction, for prediction of metabolic clearance this has been much less so. The depth of an UWL surrounding a membrane is greatest in an unstirred system and may be reduced by shaking or agitation (Williams et al., 1990; Avdeef et al., 2004; Shibayama et al., 2015) . However, a widely held assumption persists that vigorous shaking has a detrimental effect on the structural integrity of isolated hepatocytes (Berry et al., 1991; Seglen, 2013) and consequently clearance assays are often performed under static or inadequately agitated conditions. When underprediction of clearance was examined in relation to passive permeability using reported PAMPA, caco-2 assay or empirical in silico methods, no relationship was apparent (Hallifax et al., 2012) . However, considering the incidence of sub-optimal protocols for permeability assays (Karlsson and Artursson, 1991; Avdeef et al., 2004) , the lack of relationship may be false and further investigation into the potential limitation of passive permeation of drugs into hepatocytes is warranted.
In the present study, examination of the roles of both the UWL and passive permeability on in vitro assay of intrinsic metabolic clearance focussed on drugs predominantly cleared by P450-mediated metabolism in the relatively robust and reproducible rat suspended hepatocyte system. The effect of supplementation of the P450 co-factor NADPH and its metabolic precursor nicotinamide was examined in freshly isolated or cryopreserved hepatocytes with and without purification using Percoll.
The influence of the UWL and permeability was investigated using a combination of controlled permeabilisation and shaking. The plant glycoside saponin was utilised to create pores in the plasma membrane permeable to drug molecules leaving internal membrane structures intact (Cook et al., 1983; Katz and Wals, 1985) . Additionally, hepatocytes were subjected to gross membrane destruction by ultra-sonication to provide a system in which neither the plasma membrane permeability barrier nor an equivalent-sized UWL were present.
Materials and Methods
This article has not been copyedited and formatted. The final version may differ from this version. 
Preparation of fresh hepatocyte suspensions
Male Sprague Dawley rats weighing 250-300g were supplied by Charles River Laboratories (Margate, UK). Animals were culled by CO 2 asphyxiation and cervical dislocation. Hepatocytes were prepared using the collagenase perfusion method described by Griffin and Houston (2004) . Briefly, this involves ex vivo perfusion of the liver lobes, firstly with EBSS containing EGTA followed by a wash-out period (EBSS only) and secondly with EBSS containing CaCl 2 , trypsin inhibitor and collagenase to facilitate digestion of the tissue. Hepatocytes are dissociated by gentle agitation of the perfused liver lobe in ice cold WME, followed by filtration through 100 µm nylon mesh (Plastok Associates Ltd., Merseyside, UK) before washing via centrifugation (29 x g for 3 minutes followed by 16 x g for 3 minutes with removal of supernatant and resuspension of cell pellet in WME between each step).
Preparation of cryopreserved hepatocyte suspensions
Cryopreserved male Sprague Dawley rat hepatocytes (pool of eight animals) were purchased from Tebu-Bio Ltd. (supplied by Sekisui XenoTech LLC (Kansas, USA)) and stored in the vapour phase of liquid nitrogen. For each experiment two vials of cryopreserved hepatocytes were thawed simultaneously; one was centrifuged at 100 x g for 5 minutes in the DMEM containing isotonic Percoll This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on December 12, 2017 as DOI: 10.1124 at ASPET Journals on January 6, 2018 dmd.aspetjournals.org Downloaded from DMD#78949 7 (as per the supplier's instructions) (Percoll-purified) and the other centrifuged at 60 x g for 3 minutes in DMEM (unpurified).
Cryopreserved human hepatocytes (pool of 20 donors) were purchased from Bioreclamation IVT (Brussels, Belgium). After thawing cells were centrifuged at 50 x g for 5 minutes in InVitroGRO CP medium.
Determination of cell viability
After centrifugation, all cell preparations were re-suspended in a small volume of WME supplemented with HEPES (final concentration 24 mM), pH 7.4. This solution was used as the incubation medium for all hepatocyte studies. Viability was measured by the proportion of cells excluding the azo dye trypan blue. 50 µl of cell suspension was diluted into 400 µl of DPBS plus 50 µl of 0.4% trypan blue.
Aliquots were loaded into a haemocytometer and counted under a light microscope to determine total cell number and trypan blue-stained number. Hepatocytes were subsequently diluted to the required density in WME accordingly.
The viability of freshly isolated rat hepatocytes was ≥ 80%; the viability of cryopreserved rat hepatocytes, which were divided between unpurified and Percoll-purified (as described in preparation of cryopreserved hepatocyte suspensions), is given in Table 3 ; the viability of cryopreserved human hepatocytes was ≥ 91%.
Preparation of permeabilised/sonicated hepatocyte suspensions
Saponin-permeabilised hepatocytes were produced by pre-incubation of fresh rat hepatocytes
(1 x 10 6 viable cells/ml (midazolam, propranolol, saquinavir incubations) or 2 x 10 6 viable cells/ml (tolbutamide incubations)) with 0.01% w/v saponin (0.5% WME solution) for 5 minutes; cell viability was checked before use. The concentration of saponin was pre-determined as the minimum required to render > 95% of cells non-viable according to trypan blue exclusion. Sonicated hepatocytes were prepared using an ultrasonic probe homogeniser (Omni Ruptor 400, CamLab Ltd., Cambridge, UK); 1 x 10 6 viable cells/ml were sonicated for 8 x 1 second pulses at 50% power and the resulting suspension was viewed under the microscope to confirm a lack of intact cells before use. Preliminary investigation showed that this treatment caused loss of cell structural integrity and complete loss of drug metabolic activity in the absence of supplemented NADPH. 
Selection of substrate and concentration
To meet the overall aims of this study, the focus was on compounds with predominantly passive disposition including metabolism by CYP enzymes, primarily midazolam (CYP3A - Patki et al., 2003) and propranolol (CYP2D -McGinnity et al., 2000; Sten et al., 2006) . Other drugs were selected to include acids and bases and a CYP-metabolised substrate with permeation limitation, namely saquinavir (CYP3A - Eagling et al., 2002; Usansky et al., 2008) .
Substrate concentration (for depletion) was either based upon equivalent published experiments and/or reported K m (midazolam - Jones and Houston, 2004; Brown et al., 2007a; tolbutamide -Ashforth et al., 1995; Griffin and Houston, 2004) , or, where information was absent or variable, set as low as practicable to avoid enzyme saturation while allowing for quantitative determination of the depletion profile; in practice this was considered achieved at 0.1 µM.
Hepatocyte incubations and sample analysis
Rat hepatocytes prepared as above were diluted to twice the required incubation concentration (Supplemental Table 1 ) based upon original estimates of cell density (including permeabilised and sonicated cells). Incubations were conducted in Nunc™ round-bottomed 0.5 ml 96-well polypropylene plates (Thermo Fisher Scientific Ltd., Loughborough, UK), on a Heidolph Titramax 1000 microtiterplate shaker (Heidolph, Schwabach, Germany) at 37°C, either unshaken or at an agitation rate of 900 rpm. This agitation rate was optimised based on the observed CL int of midazolam in rat hepatocytes across different shaking speeds and the practical limitations of this method. Hepatocytes (60 µl cell suspension/well) were pre-incubated for 5 minutes with 24 µl of either WME (intact hepatocytes) or WME containing NADPH (permeabilised/sonicated hepatocytes); 36 µl of substrate (WME solution) was added to initiate the reaction (total incubation volume, 120 µl). NADPH and a precursor, nicotinamide, were also added to some intact hepatocytes to assess their effect (Supplemental Table 1 ). Although some controversy exists, it appears likely that nicotinamide can be taken up by hepatocytes whereas NADPH cannot (Nikiforov et al., 2011; Pittelli et al., 2011 Cryopreserved human hepatocytes prepared as above were diluted to twice the required final concentration (0.25, 0.4 and 1 x 10 6 cells/ml, midazolam, saquinavir and propranolol, respectively).
Incubations were conducted as above at 0.1 µM (midazolam, propranolol) or 1 µM (midazolam, propranolol, saquinavir); at least six time points (duplicate) were included over 60 minutes to produce a substrate depletion time profile.
Terminated incubations were stored at -20°C for at least one hour before centrifugation at 1125 x g for acetate/methanol or a mixture of both according to pre-determined gradients for each analyte; flow rate was 1 ml/min with 0.25 ml directed into the MS. The MS conditions were standard for either positive or negative ion mode with mass transitions set according to manual tuning. Calibration curves were prepared using untreated hepatocytes/medium spiked with drug and analysed alongside samples to allow quantification using QuanLynx software (MassLynx v4.1, Waters, Watford, UK).
Intrinsic clearance of total drug
Intrinsic clearance was determined by substrate depletion rate (except tolbutamidesee below).
Drug concentrations were fitted to incubation time using a single exponential function (Equation 1) in GraFit (v7.0.03, Erithacus Software Ltd., Horley, UK).
This article has not been copyedited and formatted. The final version may differ from this version. where C is the substrate concentration at any given time (t), C 0 is the substrate concentration in the incubation medium at time 0 and k is the elimination rate constant, substituted into Equation 2 for calculation of intrinsic clearance (CL int ) (µl/min/10 6 cells).
where V is the incubation volume (µl) and No. of cells is the number of cells in the incubation/10 6 .
Tolbutamide CL int was determined by measurement of the formation of 4'-hydroxy tolbutamide over time. Four low substrate concentrations (1, 2.5, 5 and 10 µM) were chosen to verify maximum rate below the reported K m of tolbutamide 4'-hydroxylation in rat hepatocytes (Ashforth et al., 1995; Griffin and Houston, 2004) by linearity of metabolite formation rate with initial concentration. CL int was calculated as the slope determined by linear regression of the plot of reaction velocity against substrate concentration.
Intrinsic clearance of unbound drug
As the viability and therefore total cell number was significantly different between preparations of unpurified and Percoll-purified cryopreserved rat hepatocytes, unbound intrinsic clearance (CL int,u ) was calculated using Equation 4, for comparison of metabolic activity.
where fu heps (Equation 5) is the fraction unbound in the hepatocyte incubation, based on total cell number.
where logP/D is the logP value for basic and neutral drugs and the logD value for acidic drugs and V R is the volume ratio of hepatocytes to medium (0.005 for 1 x 10 6 cells/ml) (Kilford et al., 2008; Brown et al., 2007b) .
Physiological scaling of intrinsic clearance
For comparison to in vivo data, hepatocyte CL int (µl/min/10 6 cells) was corrected for incubational binding (fu heps ) and scaled to predicted in vivo CL int,u (Equation 6).
This article has not been copyedited and formatted. The final version may differ from this version. (6) Hepatocellularity of 120 x 10 6 hepatocytes/g liver was used for both human (Hakooz et al., 2006) and rat (Bayliss et al., 1999) and liver weight relative to bodyweight (LW) was 21.4 g/kg bodyweight for human and 40 g/kg bodyweight for rat (Davies and Morris, 1993) .
Observed in vivo CL int,u values are as reported in Wood et al. (2017) .
Theoretical considerations on potentially rate limiting processes
For drugs which enter hepatocytes predominantly passively, three sequential, potentially rate limiting processes (and their apparent CL int terms) can be envisaged, mechanistically: diffusion through the UWL (CL UWL ), diffusion through the plasma membrane (CL mem ) and intrinsic metabolic clearance (CL int,met 
CL mem can then be obtained by rearrangement of eq. 7 to eq. 8. 
CL UWL can be obtained by rearrangement of eq. 9 to eq. 10.
The results of the experiments conducted were explored to assess how the hypothetical apparent CL int values could be experimentally resolved. The first six following sections report sequential investigations which progress from fundamental assessment of the metabolic activity of non-viable cells through attempted removal of progressive passive rate limiting barriers (UWL, plasma membrane) preceding drug metabolism in in vitro incubation using rat hepatocytes. The impact/necessity for cofactor (NADPH) supplementation was assessed. Permeabilisation of plasma membranes using saponin was employed to reduce/remove any cell permeation barrier for passively permeating drugs. Shaking of hepatocyte suspensions was used to reduce/remove any UWL barrier external to suspended hepatocytes and finally ultrasonication of hepatocytes was used where necessary to ensure comprehensive barrier removal.
Results

Overview of studies
Subsequent sections report the impact of optimised methods in human hepatocytes and on prediction of clearance in vivo from both species.
Effect of Percoll purification on rat hepatocyte CL int
As anticipated, cryopreserved rat hepatocytes purified with Percoll had significantly (p < 0.01) greater viability as determined by trypan blue exclusion than unpurified hepatocytes (Table 1) . Consequently, the total cell concentrations in purified preparations were substantially lower (24 -28%) and to account for any resulting differences in non-specific incubational binding, CL int,u was used to compare metabolic activity, using total cell concentration to estimate fu heps .
Although the population of non-viable cells is not expected to influence the CL int,u , midazolam and propranolol CL int,u , expressed per number of viable cells (as is common practice), was considerably greater in unpurified hepatocytes compared to Percoll-purified hepatocytes; the apparent loss of activity in Percoll-purified preparations was 25% and 31% for midazolam and propranolol respectively (without NADPH, Table 1 ). Yet when CL int,u was normalised to total cell number, the activity in unpurified and Percoll-purified hepatocytes was similar (Table 1 ), suggesting that those cells deemed non-viable (stained with trypan blue) significantly contributed to the metabolism of both drugs. Also, the difference in activity expressed per viable cell number between preparations was in proportion to the difference in number of non-viable cells, strongly suggesting that metabolic activity is approximately equivalent in viable and non-viable hepatocytes (rather than due to a loss of activity in purified viable cells).
Effect of cofactor supplementation on rat hepatocyte CL int
This article has not been copyedited and formatted. The final version may differ from this version. In fresh hepatocytes, there was no difference in midazolam CL int in the presence or absence of nicotinamide (208 +/-49 vs. 212 +/-73 µl/min/10 6 cells, respectively). However, there was an average increase in CL int of midazolam of about 25% in the presence of NADPH (264 +/-86 vs. 212 +/-57 µl/min/10 6 cells, respectively), although again this was not statistically significant (data not tabulated).
When NADPH was added to unpurified cryopreserved rat hepatocytes, there was a substantial (52%) increase in CL int,u of midazolam (Table 1 ) and this was reflected in a similar (41%) increase in propranolol CL int,u under the same conditions. For Percoll-purified cryopreserved hepatocytes however, there was no discernible change in CL int,u (Table 1) . These findings not only indicate a substantial availability of NADPH to unpurified hepatocytes (evidencing a permeability barrier to this cofactor in intact cells), but also show substantial NADPH-limited enzyme activity in 'non-viable' cells.
The concentration of the precursor of cytosolically produced NADPH, NADP+, has been estimated to be about 200 µM in rat hepatocyte cytosol (based on Reiss et al., 1984) and the ratio NADPH/NADP has been reported as 4.2 in rat hepatocytes (Fabregat et al., 1985) ; assuming normal concentrations of NADPH of this order, it can be appreciated that significant exhaustion of this cofactor might occur in leaky cells.
Comparison of intact and saponin-permeabilised rat hepatocyte CL int
Fresh rat hepatocytes treated with 0.01% w/v saponin for 5 minutes pre-incubation ubiquitously displayed trypan blue staining and hence were deemed entirely non-viable by this test. Saponin is a selective membrane permeabilisation agent at this concentration, predominantly confining pore formation to the plasma membrane; the cells in question remained visibly intact, supporting such selective damage.
The CL int of midazolam, propranolol and saquinavir (with potentially significant differences in permeability), was compared between fresh intact hepatocytes and saponin-permeabilised hepatocytes with and without exogenous NADPH supplementation. CL int values were normalised to initial total cell number.
Saponin treatment resulted in effectively complete inhibition of midazolam, propranolol and saquinavir clearance (Table 2, Figure 1 ). However, addition of 1 mM NADPH to these preparations restored substrate metabolism to levels either consistent with (midazolam), or substantially greater than 
Effect of shaking on CL int in intact rat hepatocytes
12 well-characterised substrates of multiple metabolic pathways, encompassing a wide range of in vivo intrinsic clearance and potentially rate-limiting permeability were selected for comparison of static and shaken clearance assays. With the exception of tolbutamide, the CL int of all drugs was considerably increased (between 2.8-and 5.5-fold) in shaken incubations compared to static; this was statistically significant for 10 of 11 remaining compounds (Table 3 ). There was an apparent tendency for fold increase in CL int caused by shaking to increase with increasing CL int (taken as the maximal, shaken value) in an apparently non-linear way; given the large range in CL int examined, this suggests a maximum shaking effect of about 5-fold ( Figure 2 ).
Effect of prior shaking on static rat hepatocyte CL int
To verify a lack of membrane damage caused by potential mechanical stress of shaking leading to enhanced metabolism of substrate, the CL int of midazolam was measured in static incubation of rat hepatocytes immediately following either a static or shaken (900 rpm) 15 minute pre-incubation. There was no difference in midazolam CL int between static (71 ± 13 μl/min/10 6 cells) and shaken (62 ± 4 μl/min/10 6 cells) pre-incubations, indicating that shaking does not permanently alter the membrane permeability of hepatocytes.
Absorption of trypan blue by rat hepatocytes during shaking
To assess the possibility of reversible membrane leakage during incubation shaking, fresh rat hepatocytes were shaken for 5 minutes at 37°C either after pre-incubation (5 minutes) with trypan blue (according to viability assay), immediately after addition of trypan blue, or without trypan blue addition until immediately after
shaking. There was no significant difference in viability between the three treatments (82.5 +/-3.8%, 85.2 +/-1.2%, 83.1 +/-4.1%, respectively), demonstrating a complete lack of plasma membrane leakage to the azo dye (Mol. Wt. 872) caused by shaking and thereby indicating likely lack of leakage to other small molecules under the same condition.
Effect of shaking on CL int in saponin-permeabilised rat hepatocytes
Four substrates were selected for investigation of the impact of shaking on permeabilised hepatocytes (Table 4 ). To clarify trends otherwise obscured by experimental variability, individual incubation replicates (by cell preparation batch) are shown (Figure 3) . In intact cells, there was a clear tendency toward increased CL int between static and shaken cells for midazolam, propranolol and saquinavir ( Figure 3 , A-C). However, for the same drugs in permeabilised cells, there was no clear trend of increased CL int (with shaking) except for saquinavir (Figure 3, C) . Also, there was little difference in CL int between shaken intact cells and static permeabilised cells for any of these three compounds, indicating substantial removal of the apparent UWL. In the single case of saquinavir, the positive effect of shaking on permeabilised cells indicated removal of a significant UWL associated with a more severe membrane barrier for this compound. In contrast to the three other drugs, tolbutamide CL int showed no increase during shaking in either intact or permeabilised cells (Figure 3, D) ;
conversely, there were indications of a decrease in tolbutamide CL int with shaking (more pronounced for permeabilised cells) but this lacked statistical significance for the number of replicates used and, at present, there would be no mechanistic explanation for this. The overall directional impactwhere significant -is indicated in Figure 3 to aid interpretation of the drug-dependent and conditiondependent effects.
Effect of shaking on saquinavir CL int in ultra-sonicated rat hepatocytes
There was no significant difference in the CL int of saquinavir between static (668 ± 239 μl/min/10 6 cells) and shaken incubations (746 ± 281 μl/min/10 6 cells) of ultra-sonicated rat hepatocytes.
Therefore, in contrast to saponin-permeabilised cells, the CL int of saquinavir in sonicated cells was maximal in both static and shaking conditions, indicating complete removal of both the residual membrane barrier (after saponin permeabilisation) and its associated UWL, by sonication.
A comparison of activity between intact, saponin-permeabilised and sonicated hepatocytes is shown in Figure 4 .
Effect of shaking on CL int in human hepatocytes
Having established the critical effect of shaking on drug CL int determinations in rat hepatocytes, it was pertinent to confirm the impact for human hepatocytes because of implications for clinical prediction.
Following similar experiments to those already described, the CL int of midazolam (1 μM) was not affected by shaking (36 +/-1 μl/min/10 6 cells) compared with static incubation (38 +/-15 μl/min/10 6 cells) in human hepatocytes. However, CL int of both propranolol at 1 μM (7 +/-2 μl/min/10 6 cells vs. 14 +/-2 μl/min/10 6 cells) and saquinavir at 1 μM (35 +/-4 μl/min/10 6 cells vs. 98 +/-27 μl/min/10 6 cells) 
Effect of shaking of hepatocytes on prediction of in vivo CL int
In rat, scaled in vitro CL int,u (ml/min/kg) was compared to in vivo CL int,u (ml/min/kg) derived from observed CL h literature data (Table 5 ). In static incubations of rat hepatocytes, 5/12 drugs were predicted within 2-fold, 2/12 predicted above 2-fold and 5/12 predicted below 2-fold. In shaken incubations, 6/12 drugs were within 2-fold, 5/12 above, and 1/12 below 2-fold. Excluding tolbutamide (slowly cleared), the increase in CL int due to shaking was between 3-and 5-fold. The in vivo CL int for these substrates ranged between about 250 and 3300 ml/min/kg and in a recent analysis of published CL int from rat hepatocytes (n = 128), the underprediction of in vivo CL int was on average 5.9-fold for between 100-1000 ml/min/kg (Wood et al., 2017) representing a similar shift in CL int and potential improvement in prediction. However, the reported ratio of in vitro CL int,u / in vivo CL int,u for the drugs used here ranged between 0.1 and 5.1 and so this group of drugs included over-as well as underpredictions of CL int,u ; the overpredicted drugs were chlorpromazine, naloxone, verapamil, propafenone and saquinavir, the latter two designated BDDCS Class 2 (all others, except tolbutamide are Class 1). Overall, for rat, there was no clear relationship between increase in CL int due to shaking and prediction accuracy.
In human hepatocytes, as indicated earlier, propranolol and saquinavir, although not midazolam, showed increased CL int with shaking (Table 6 ). For propranolol, this resulted in underprediction of 5.8fold at 1 µM and 3.7-fold at 0.1 µM, compared with the average reported prediction of 6.7-fold underprediction for this drug and the average underprediction of 12-fold for the CL int,u range of 100-1000 ml/min/kg (Wood et al., 2017) . Saquinavir was underpredicted by 12-fold in shaken incubations compared to 34-fold in static incubations (1 μM); there is no previously reported prediction for this drug, but the average underprediction for the in vivo CL int,u range 1000-10000 ml/min/kg is 30-fold.
Midazolam in vivo CL int,u was underpredicted by 3.9-and 3.1-fold in static and shaken incubations respectively (0.1 μM) compared with 9.3-fold underprediction reported in the literature (Wood et al., This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Prediction of clearance from in vitro systems has been recognised for many years as not mechanistically quantitative (Iwatsubo et al., 1997; Hallifax and Houston, 2009) . Explanations for this have focussed on physiological scaling, liver dispersion models, plasma protein binding inaccuracies as well as in vitro methodology, but without comprehensive validation. Among recent re-appraisal of experimental methodology (Bowman and Benet, 2016; Wood et al., 2017) a tendency for clearance prediction to become increasingly inaccurate with increasing in vivo intrinsic clearance, independent of in vitro system and species, has been highlighted. Hence fundamental aspects of the intrinsic clearance assay -cell viability and potentially rate limiting UWL and membrane barriers -have been examined, using rat hepatocytes.
Hepatocytes deemed non-viable by the standard trypan blue exclusion assay were metabolically active to an extent comparable with 'viable' cells (for P450 substrates midazolam and propranolol).
Further, enhanced levels of metabolic capacity were evident upon supplementation of the 'non-viable' cells with the P450 cofactor NADPH. Hepatocytes treated with the pore forming agent saponin and incubated in the presence of 1 mM NADPH gave CL int for midazolam, propranolol and saquinavir comparable with intact cells, verifying CYP enzyme functionality in hepatocytes with porous plasma membranes. For permeabilised cells, the external dispersion of NADPH appeared to be the single confounding impediment to clearancelack of supplemented NADPH halted metabolism. Therefore, those normally-prepared hepatocytes which are susceptible to absorption of trypan blue, appear not to lose this cofactor to any significant extent. Protocols for CL int assay typically preclude hepatocyte batches below a designated threshold of viability but otherwise express CL int per number of cells which exclude trypan blue ('viable'). The findings here, however, imply that such estimates of intrinsic clearance may be compromised by the metabolic viability of 'non-viable' cells; in addition, a differential in permeability barrier may exist between cells of different condition which could skew apparent intrinsic clearance measurement in cases where this was rate limiting.
A lack of methodological consistency among CL int assays in the literature has been highlighted recently (Wood et al., 2017) , including to what extent, if any, shaking of incubates was employed;
This article has not been copyedited and formatted. The final version may differ from this version. UWL effects, which although well recognised in permeability assays (Avdeef et al., 2004) have not been fully addressed in the context of CL int assays. Compared to static incubations, shaken rat hepatocytes gave up to 5-fold greater CL int , for a range of metabolically cleared drugs indicating a substantial rate limitation due to the UWL; the increase appeared to depend on CL int up to about 500 µl/min/10 6 cells (equivalent to 430 ml/min/kg) but was constant at higher CL int levels, indicating an upper limit to the impact of the UWL (possible reflecting prevailing plasma membrane permeability limitation). The CL int was dependent on shaking speed (optimised to 900 rpm for 96 well plates) and therefore previous studies employing shaking could still have incurred rate limitation if not optimised.
It was experimentally verified that the impact of shaking on CL int was not due to damage (leakage) to the plasma membrane.
When hepatocytes were permeabilised with saponin, there was an increase in CL int in static incubations (compared to intact cells) and hence the effect of shaking was reduced, depending on the drug, implying a reduced UWL associated with a permeabilised membrane. In permeabilised hepatocytes, CL int of midazolam and propranolol was little affected by shaking, whereas CL int of saquinavir was substantially increased. Pores in membranes are reported to allow flux of water molecules which can lead to breakdown of the UWL (Korjamo et al., 2009 ). The observation that shaking clearly increased CL int for saquinavir in permeabilised cells beyond that in shaken intact cells indicates, importantly, that the plasma membrane was contributing to rate limitation. This was expected for saquinavir whose CL int has been demonstrated to be uptake rate limited in rat hepatocytes (Parker and Houston, 2008) , with approximately equal contribution between active and passive uptake mechanisms (Yabe et al., 2011) . Using ultrasonicated cells, where membranes were effectively destroyed, saquinavir CL int was not affected by shaking and was equivalent to the (maximal) values obtained in shaken permeabilised cells, providing evidence that the plasma membrane can be effective as a barrier in cells permeabilised with saponin, possibly by involvement of an accompanying and effective UWL. In contrast to the three highly cleared drugs, tolbutamide CL int was not increased by shaking or permeabilisation, as would be expected for a slowly metabolised drug, for which the overall clearance is limited solely by metabolic rate.
The foregoing provides experimental means to identify rate limiting processes in vitro which would otherwise confound accurate determination of CL int . For drugs with predominantly passive hepatic This article has not been copyedited and formatted. The final version may differ from this version. uptake, three sequential mechanistic processes can be appropriately assumed ( Figure 5 ): diffusion through the apparent UWL (CL UWL ), diffusion through the plasma membrane (CL mem ) and intrinsic metabolic clearance (CL int,met represented by the apparent CL int observed in static incubations of intact hepatocytes and can be determined by equations 9 and 10. Midazolam, propranolol and saquinavir are exemplary drugs for which rat CL int is rate limited by the UWL in the absence of adequate shaking in vitro. Figure 6 illustrates how the CL int,app is influenced by changes to CL UWL and CL mem (all relative to CL int,met ).
Notably, CL UWL and CL mem must be at least 10-fold greater than CL int,met for CL int,app to approach CL int,met . A very low CL UWL or CL mem (relative to CL int,met ) severely restricts CL int,app.
So far, the optimisation of in vitro assay of CL int to eliminate artefactual and confounding dispositional factors has been discussed. Nevertheless, extrapolation to in vivo CL int is likely to be confounded by the lack of comparability between hepatocytes and the intact liver. For example, a lack of equivalent UWL in the hepatic interstitial space (Space of Disse) might be assumed; an UWL of 10 μm has been estimated (Bass and Pond, 1987) although this exceeds the diameter of the space itself (1-2 μm, Barry and Diamond, 1984) . But, despite this apparently minimal barrier in the liver, extraction of highly permeably drugs by the isolated perfused rat liver has been shown to be limited by an UWL (Ichikawa et al., 1992) . In this study, uptake of highly permeable drugs was relatively independent of free fraction (when albumin was added to the perfusate) compared to less permeable drugsconsistent with the 'albumin mediated transport' phenomenon, but explained by rate limiting diffusion through the UWL. From a mechanistic perspective, extrapolation from in vitro to in vivo should be based on minimisation of artefactual in vitro UWL effects and so it is recommended that shaking of hepatocyte incubations be optimised to maximise CL int as described. This would allow scope, for example, to reappraise inclusion of plasma proteins in these assays. Beyond this, the hepatocyte plasma membrane would remain a potential barrier to highly cleared drugs both in vitro and in vivo and this could include drugs considered highly permeable, such as propranolol. It is not known, however, if quantitative differences in permeation between in vitro and in vivo exist. In cases where permeability may be Together, these findings indicate the potentially critical importance of both the apparent UWL and the hepatocyte membrane in vitro, for successful progress of prediction methodology. This strongly advocates a multi-track experimental approach for elucidating drug hepatic CL int , allowing the disposition processes to be resolved. As a minimum, assay of investigative compound disposition using isolated hepatocytes in parallel with microsomal CL int assay is recommended for all drug types, including highly permeable/metabolised drugs (BDDCS Class 1 or 2); such approaches have been advocated previously for drugs dependent on active hepatic uptake for clearance (Umehara and Camenisch, 2012) . A yet more direct comparison, using intact and permeabilised hepatocytes, as shown in this study, would allow estimation of clearance to be flagged when this is rate-limited by passive permeability (in the absence of knowing that this limitation is accurately matched in vivo).
Given the trend towards drugs which depend on hepatic uptake transport, more investigation is required (particularly with human hepatocytes) to resolve the quantitative capabilities of in vitro systems and improve their methodology, particularly so that both active and passive permeation are sufficiently representative of in vivo. (Table 4) ; CL UWL determined analogous to CL mem using CL met / CLint,app derived from static intact v shaken permeabilised CL int (Table 4) ].
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